Your browser doesn't support javascript.
loading
Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy.
Alvarez, Maite; Molina, Carmen; De Andrea, Carlos E; Fernandez-Sendin, Myriam; Villalba, Maria; Gonzalez-Gomariz, Jose; Ochoa, Maria Carmen; Teijeira, Alvaro; Glez-Vaz, Javier; Aranda, Fernando; Sanmamed, Miguel F; Rodriguez-Ruiz, Maria E; Fan, Xinyi; Shen, Wen H; Berraondo, Pedro; Quintero, Marisol; Melero, Ignacio.
Afiliação
  • Alvarez M; Immunology and Immunotherapy, Center for Applied Medical Research (CIMA). University of Navarra, Pamplona, Spain imelero@unav.es malvarezr@unav.es.
  • Molina C; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
  • De Andrea CE; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain.
  • Fernandez-Sendin M; Immunology and Immunotherapy, Center for Applied Medical Research (CIMA). University of Navarra, Pamplona, Spain.
  • Villalba M; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
  • Gonzalez-Gomariz J; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
  • Ochoa MC; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain.
  • Teijeira A; Pathology, Clinica Universidad de Navarra, Pamplona, Spain.
  • Glez-Vaz J; Immunology and Immunotherapy, Center for Applied Medical Research (CIMA). University of Navarra, Pamplona, Spain.
  • Aranda F; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
  • Sanmamed MF; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain.
  • Rodriguez-Ruiz ME; Pathology, Clinica Universidad de Navarra, Pamplona, Spain.
  • Fan X; Immunology and Immunotherapy, Center for Applied Medical Research (CIMA). University of Navarra, Pamplona, Spain.
  • Shen WH; Immunology and Immunotherapy, Center for Applied Medical Research (CIMA). University of Navarra, Pamplona, Spain.
  • Berraondo P; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
  • Quintero M; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain.
  • Melero I; Immunology and Immunotherapy, Center for Applied Medical Research (CIMA). University of Navarra, Pamplona, Spain.
J Immunother Cancer ; 9(11)2021 11.
Article em En | MEDLINE | ID: mdl-34824158
ABSTRACT

BACKGROUND:

BO-112 is a nanoplexed form of polyinosinicpolycytidylic acid that acting on toll-like receptor 3 (TLR3), melanoma differentiation-associated protein 5 (MDA5) and protein kinase RNA-activated (PKR) elicits rejection of directly injected transplanted tumors, but has only modest efficacy against distant untreated tumors. Its clinical activity has also been documented in early phase clinical trials. The 5,6-dimethylxanthenone-4-acetic acid (DMXAA) stimulator of interferon genes (STING) agonist shows a comparable pattern of efficacy when used via intratumoral injections.

METHODS:

Mice subcutaneously engrafted with bilateral MC38 and B16.OVA-derived tumors were treated with proinflammatory immunotherapy agents known to be active when intratumorally delivered. The combination of BO-112 and DMXAA was chosen given its excellent efficacy and the requirements for antitumor effects were studied on selective depletion of immune cell types and in gene-modified mouse strains lacking basic leucine zipper ATF-like transcription factor 3 (BATF3), interferon-α/ß receptor (IFNAR) or STING. Spatial requirements for the injections were studied in mice bearing three tumor lesions.

RESULTS:

BO-112 and DMXAA when co-injected in one of the lesions of mice bearing concomitant bilateral tumors frequently achieved complete local and distant antitumor efficacy. Synergistic effects were contingent on CD8 T cell lymphocytes and dependent on conventional type 1 dendritic cells, responsiveness to type I interferon (IFN) and STING function in the tumor-bearing host. Efficacy was preserved even if BO-112 and DMXAA were injected in separate lesions in a manner able to control another untreated third-party tumor. Efficacy could be further enhanced on concurrent PD-1 blockade.

CONCLUSION:

Clinically feasible co-injections of BO-112 and a STING agonist attain synergistic efficacy able to eradicate distant untreated tumor lesions.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células Dendríticas / Poli I-C / Imunoterapia Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células Dendríticas / Poli I-C / Imunoterapia Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article
...